In last trading session, Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) saw 0.52 million shares changing hands with its beta currently measuring -0.57. Company’s recent per share price level of $176.66 trading at $7.97 or 4.72% at ring of the bell on the day assigns it a market valuation of $3.49B. That closing price of MDGL’s stock is at a discount of -82.65% from its 52-week high price of $322.67 and is indicating a premium of 67.62% from its 52-week low price of $57.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 439.06K if we extend that period to 3-months.
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) trade information
Upright in the green during last session for gaining 4.72%, in the last five days MDGL remained trading in the green while hitting it’s week-highest on Friday, 11/17/23 when the stock touched $176.66 price level, adding 0.1% to its value on the day. Madrigal Pharmaceuticals Inc’s shares saw a change of -39.14% in year-to-date performance and have moved 27.24% in past 5-day. Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) showed a performance of 35.56% in past 30-days. Number of shares sold short was 3.41 million shares which calculate 7.16 days to cover the short interests.
Madrigal Pharmaceuticals Inc (MDGL) estimates and forecasts
Statistics highlight that Madrigal Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -36.13% of value to its shares in past 6 months, showing an annual growth rate of -12.13% while that of industry is 10.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to decrease by -6.40% in the current quarter and calculating -31.70% decrease in the next quarter.
And 7 analysts are in estimates of company making revenue of $30k in the next quarter that will end on Mar 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -46.66% during past 5 years. In 2023, company’s earnings growth rate is likely to be around -11.92% while estimates for its earnings growth in next 5 years are of 0.00%.
Madrigal Pharmaceuticals Inc is more likely to be releasing its next quarterly report on November 06 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)’s Major holders
Insiders are in possession of 9.90% of company’s total shares while institution are holding 85.07 percent of that, with stock having share float percentage of 94.41%. Investors also watch the number of corporate investors in a company very closely, which is 85.07% institutions for Madrigal Pharmaceuticals Inc that are currently holding shares of the company. Janus Henderson Group PLC is the top institutional holder at MDGL for having 3.04 million shares of worth $537.52 million. And as of Sep 29, 2023, it was holding 15.41% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group Inc, which was holding about 1.57 million shares on Sep 29, 2023. The number of shares represents firm’s hold over 7.97% of outstanding shares, having a total worth of $277.95 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 0.45 million shares of worth $80.05 million or 2.30% of the total outstanding shares. The later fund manager was in possession of 0.38 million shares on Jun 29, 2023, making its stake of worth around $66.72 million in the company or a holder of 1.91% of company’s stock.